
Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc. (ERNA)
WebsitePrice
Market cap
Next catalystFirst-patient dosing / Phase 1 initiation in Q1 2027, subject to IND clearanceERNA-101 — planned first-in-human Phase 1 study · Trial initiationSEC filing ↗
Cash
Chart & Events
Core Clinical
PreINDP2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
PreINDP2P3FilingApproved